Agile Therapeutics Inc's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Agile Therapeutics Inc's ROA in the second quarter of 2024?
Agile Therapeutics Inc recorded a cumulative net loss of $-16 million during 12 months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -130.17%.

However, within the Healthcare sector 904 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2024 from 4515 to 4770.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter
Y / Y Total Assets Change	19.03 %	-7.94 %	-27.99 %	-41.02 %	-61.71 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-16	-8	-14	8	3
Return On Assets (TTM)	-130.17 %	-67.27 %	-122.04 %	64.16 %	21.11 %
AGRX's Total Ranking	# 4770	# 4515	# 5556	# 70	# 234
Total Assets (TTM) in million	15	13	10	11	13
Seq. Total Assets Change	18.66 %	22.96 %	-5.82 %	-13.38 %	-8.22 %
Seq. Net Income Change	-	-	-	-	-

AGRX's 5 Years Annual ROA >> Back to AGRX Management Effectiveness >> Compare AGRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 432
Sector	# 905
Overall	# 4686

Return On Assets Statistics
High	Average	Low
64.16 %	-56.42 %	-172.98 %
(Sep 30 2023)		(Mar 31 2022)

News about Agile Therapeutics Inc Return on Assets ROA

Agile Therapeutics Inc Bolsters Financial Position, Eliminating Debt and Poised for Growth

Agile Therapeutics Inc: Eliminating Debt and Focused on Business Plan Execution
Agile Therapeutics Inc, a pharmaceutical company specializing in women’s healthcare, has announced the successful completion of its debt repayment to Perceptive Advisors. This significant development has left the company with a debt-free balance sheet, providing a strong foundation for future growth and securing investor confidence.
Having struggled with a heavy debt load in recent years, Agile Therapeutics has made remarkable progress in improving its financial position. By eliminating its remaining debt to Perceptive Advisors, the company can now focus its resources and attention on executing its business plan and pursuing strategic initiatives.

Agile Therapeutics: Pioneering Women's Healthcare with Innovative Contraceptives and Nasdaq Listing Compliance Extension

Agile Therapeutics Granted Extension by Nasdaq Hearings Panel and Provides Performance Update
Agile Therapeutics, a leading women s healthcare company focusing on the development and commercialization of innovative healthcare products, recently announced that it has been granted an extension by the Nasdaq Hearings Panel to regain compliance with the Stockholders Equity Continued Listing Requirement. The extension allows the company to continue trading on the Nasdaq Global Market until March 25, 2024. Agile Therapeutics also provided a performance update, highlighting significant achievements and future prospects.
The decision from the Nasdaq Hearings Panel to grant Agile Therapeutics an extension reflects the company s commitment to meet the listing requirements and maintain its position on the Nasdaq Global Market. By extending the compliance deadline, the panel recognizes Agile Therapeutics efforts to address the stockholders equity issue and allows the company additional time to execute its strategies effectively.
Agile Therapeutics specializes in the development and commercialization of transdermal patch-based contraceptives. Their lead product, Twirla®, is a once-weekly contraceptive patch that has received approval from the U.S. Food and Drug Administration (FDA). The extension provided by the Nasdaq Hearings Panel ensures that Agile Therapeutics can continue to promote Twirla®, allowing women to benefit from a convenient and effective birth control option.

Financial Statements
Agile Therapeutics Inc's Assets	$ 15 million	AGRX's Balance sheet
Agile Therapeutics Inc's Income	$ -12 million	Quarterly AGRX's Income Statement
AGRX's Income by Division		See AGRX's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-27.99 %	-63.79 %	-46.16 %	47.48 %	121.24 %
Total Assets in million	10	14	39	73	50
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-14	-25	-75	-52	-19
Annual Return On Assets	-141.05 %	-178.43 %	-190.41 %	-70.97 %	-37.56 %

AGRX's 5 Years Annual ROA >> Back to AGRX Management Effectiveness >> Compare AGRX ROA to its Competitors

More Return On Assets Ratios
AGRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AGRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AGRX's Competitors
Subscribers only: Roa for Agile Therapeutics Inc's Suppliers
Subscribers only: Return On Assets for AGRX's Customers

You may also want to know
AGRX's Roi	AGRX's Inventory Turnover Ratio	AGRX's Growth Rates	AGRX's Dividend Comparisons
	AGRX's Profitability Ratios	AGRX's Asset Turnover Ratio	AGRX's Dividend Growth
AGRX's Roe	AGRX's Valuation Ratios	AGRX's Financial Strength Ratios	AGRX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:14:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.